Inverse correlation between mRNA expression of plasminogen activator inhibitor-2 and lymph node metastasis in human breast cancer
- PMID: 8641985
- PMCID: PMC5921131
- DOI: 10.1111/j.1349-7006.1996.tb00249.x
Inverse correlation between mRNA expression of plasminogen activator inhibitor-2 and lymph node metastasis in human breast cancer
Abstract
We examined mRNA expressions of urokinase-type plasminogen activator (u-PA), its specific receptor (u-PR), and plasminogen activator inhibitors (PAI-1 and PAI-2) in 50 human breast cancers by the reverse transcriptase-polymerase chain reaction method. The expressions of the genes are discussed in relation to the clinicopathological findings. In the overall population in breast cancers, a low level of PAI-2 expression was significantly associated with lymph node involvement (P < 0.0001). The u-PA, u-PR, and PAM expressions tended to be at high levels in such metastatic cancers. Also, positive expression of u-PA, u-PR, and PAI-1 was significantly correlated with negative expression of PAI-2. These results indicate that PAI-2 may play a critical role in the regulation of extracellular matrix degradation during tumor cell invasion and metastasis, and the expression of PAI-2 may be useful as a marker to evaluate the prognosis of breast cancers.
Similar articles
-
Significance of plasminogen activator inhibitor 2 as a prognostic marker in primary lung cancer: association of decreased plasminogen activator inhibitor 2 with lymph node metastasis.Br J Cancer. 1998 Sep;78(6):833-9. doi: 10.1038/bjc.1998.588. Br J Cancer. 1998. PMID: 9743310 Free PMC article.
-
Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues.J Pathol. 1997 Dec;183(4):388-97. doi: 10.1002/(SICI)1096-9896(199712)183:4<388::AID-PATH943>3.0.CO;2-I. J Pathol. 1997. PMID: 9496254
-
Antigen levels of urokinase type plasminogen activator and its inhibitors in primary breast cancer.Z Naturforsch C J Biosci. 2002 Mar-Apr;57(3-4):366-71. doi: 10.1515/znc-2002-3-428. Z Naturforsch C J Biosci. 2002. PMID: 12064742
-
Messenger RNA determination of estrogen receptor, progesterone receptor, pS2, and plasminogen activator inhibitor-1 by competitive reverse transcription-polymerase chain reaction in human breast cancer.Clin Cancer Res. 1999 Jun;5(6):1497-502. Clin Cancer Res. 1999. PMID: 10389938
-
[The clinical prospects for the study of the plasminogen activation system in breast cancer].Vestn Ross Akad Med Nauk. 1999;(8):58-61. Vestn Ross Akad Med Nauk. 1999. PMID: 10487126 Review. Russian.
Cited by
-
Decreased expression of SERPINB1 correlates with tumor invasion and poor prognosis in hepatocellular carcinoma.J Mol Histol. 2014 Feb;45(1):59-68. doi: 10.1007/s10735-013-9529-0. Epub 2013 Oct 9. J Mol Histol. 2014. PMID: 24105272
-
SerpinB2 is involved in cellular response upon UV irradiation.Sci Rep. 2019 Feb 26;9(1):2753. doi: 10.1038/s41598-019-39073-w. Sci Rep. 2019. PMID: 30808882 Free PMC article.
-
Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer.BMC Cancer. 2006 Aug 31;6:216. doi: 10.1186/1471-2407-6-216. BMC Cancer. 2006. PMID: 16945123 Free PMC article.
-
Significance of plasminogen activator inhibitor 2 as a prognostic marker in primary lung cancer: association of decreased plasminogen activator inhibitor 2 with lymph node metastasis.Br J Cancer. 1998 Sep;78(6):833-9. doi: 10.1038/bjc.1998.588. Br J Cancer. 1998. PMID: 9743310 Free PMC article.
-
SERPINB5 is a prognostic biomarker and promotes proliferation, metastasis and epithelial-mesenchymal transition (EMT) in lung adenocarcinoma.Thorac Cancer. 2023 Aug;14(23):2275-2287. doi: 10.1111/1759-7714.15013. Epub 2023 Jul 9. Thorac Cancer. 2023. PMID: 37424293 Free PMC article.
References
-
- ) Danø , K. , Andreasen , P. A. , Grøndahl‐Hansen , J. , Kristensen , P. , Nielsen , L. S. and Skriver , L.Plasminogen activators, tissue degradation, and cancer . Adv. Cancer Res. , 44 , 139 – 266 ( 1985. ). - PubMed
-
- ) Duffy , M. J. , Reilly , D. , O'Sullivan , C. , O'Higgins , N. , Fennelly , J. J. and Andreasen , P.Urokinase‐plasminogen activator, a new and independent prognostic marker in breast cancer . Cancer Res. , 50 , 6827 – 6829 ( 1990. ). - PubMed
-
- ) Ganesh , S. , Sier , C. F. M. , Griffioen , G. , Vloedgraven , H. J. M. , de Boer , A. , Welvaart , K. , van de Velde , C. J. H. , van Krieken , J. H. J. M. , Verheijen , J. H. , Lamers , C. B. H. W. and Verspaget , H. W.Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer . Cancer Res. , 54 , 4065 – 4071 ( 1994. ). - PubMed
-
- ) Grøndahl‐Hansen , J. , Christensen , I. J. , Rosenquist , C. , Brünner , N. , Mouridsen , H. T. , Danø , K. and Blichert‐Toft , M.High levels of urokinase‐type plasminogen activator and its inhibitor PAI‐1 in cytosolic extracts of breast carcinomas are associated with poor prognosis . Cancer Res. , 53 , 2513 – 2521 ( 1993. ). - PubMed
-
- ) Del Vecchio , S. , Stoppelli , M. P. , Carriero , M. V. , Fonti , R. , Massa , O. , Li , P. Y. , Botti , G. , Cerra , M. , D'Aiuto , G. , Esposito , G. and Salvatore , M.Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels . Cancer Res. , 53 , 3198 – 3206 ( 1993. ). - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous